July 05, 2016
2 min watch
Save

VIDEO: GLP-1 receptor agonists demonstrate increased efficacy with insulin in combination therapies

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS — In this video, Philip D. Home, DM, DPhil, MRCP, of Newcastle University in the United Kingdom, discusses updates in research involving glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors that were presented at the American Diabetes Association Scientific Sessions.

Home mentions how there were discussions at the meeting that looked at what kind of mechanisms might have been behind why ketoacidosis might occur in patients with type 1 diabetes who use SGLT2 inhibitors off-label.

He also discusses how data indicated that the use of GLP-1 receptor agonists reduced weight gain as well as hypoglycemia in patients with type 1 diabetes.